Biochemical modulation of the catabolism and tissue uptake of the anticancer drug 5-fluorouracil by 5-bromovinyluracil: Assessment with metabolic 19F MR imaging

Magnetic Resonance in Medicine

Volumn 42, Issue 5, 1999, Pages 936-943

  Brix, Gunnar ^a,b   Belleman, Matthias E ^b,c   Haberkorn, Uwe ^b,d  

^a BUNDESAMT FÜR STRAHLENSCHUTZ   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF APPLIED SCIENCES JENA   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

5 fluorouracil; 5 bromovinyluracil; Chemotherapy; Experimental neoplasms; Magnetic resonance imaging

Indexed keywords

AMINO ACIDS; ANTHROPOMETRY; CHEMICAL SHIFT; FOURIER TRANSFORMS; MAGNETIC RESONANCE IMAGING; METABOLISM; RATS; TUMORS;

5-BROMOVINYLURACIL; 5-FLUOROURACIL; ANTICANCER DRUG; BIOCHEMICAL MODULATIONS; BODY WEIGHT; CONTROL GROUPS; EXPERIMENTAL NEOPLASM; FOURIER; INTRAPERITONEALLY; Β-ALANINE;

CHEMOTHERAPY;

FLUOROURACIL;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG UPTAKE; LIVER CELL CARCINOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RAT;

EID: 0032730566     PISSN: 07403194     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1522-2594(199911)42:5<936::aid-mrm14>3.0.co;2-#     Document Type: Article

References (45)

1. Heidelberger CH, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer RJ, Pleven E, Scheiner J. Fluorinated pyrimidines a new class of tumour-inhibitory compounds. Nature 1959;179: 663-666.
2. Kemeny N. Current approaches to metastatic colorectal cancer. Semin Oncol 1994;21:67-75.
3. Sotos GA, Grogan L, Allegra CJ. Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treat Rev 1994;20:11-49.
4. Heidelberger C. On the rational development of a new drug: the example of the fluorinated pyrimidines. Cancer Treat Rep 1981;65:3-9.
5. Myers CE. The pharmacology of the fluoropyrimidines. Pharmacol Rev 1981;33:1-15.
6. 19F NMR. Br J Cancer 1984;50:113-117.
7. Malet-Martino MC, Martino R, Lopez A, Béteille JP, Bon M, Bernadou J, Armand JP. New approach to metabolism of 5′-deoxy-5-fluorouridine in humans with fluorine-19 NMR. Cancer Chemother Pharmacol 1984;13: 31-35.
8. 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment. Cancer Res 1988;48:1680-1688.
9. 19F MRS studies of fluoropyrimidine chemotherapy. A review. NMR Biomed 1989;2:133-141.
10. 19F magnetic resonance spectroscopy studies of the metabolism of 5-fluorouracil in murine RIF-1 tumors and liver. Cancer Res 1991;51:1384-1390.
11. 19F nuclear magnetic resonance spectroscopy. Cancer Res 1991;51:5806-5812.
12. 19F NMR spectroscopy. NMR Biomed 1991;4:274-278.
13. Wolf W, Albright MJ, Silver MS, Weber H, Reichardt U, Sauer R. Fluorine-19 NMR spectroscopic studies of the metabolism of 5-fluorouracil in the liver of patients undergoing chemotherapy. Magn Reson Imaging 1987;5:165-169.
14. 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. Proc Natl Acad Sci USA 1990;87:492-496.
15. 19F nuclear magnetic resonance spectroscopy pharmacokinetics. J Clin Oncol 1990;8:1868-1873.
16. 19F magnetic resonance spectroscopy. Br J Radiol 1990;63:547-553.
17. Semmler W, Bachert-Baumann P, Gückel F, Ermark F, Schlag P, Lorenz WJ, van Kaick G. Real-time follow-up of 5-fluorouracil metabolism in the liver of tumor patients by means of F-19 MR spectroscopy. Radiology 1990;174:141-145.
18. 19F NMR study during 5-FU chemotherapy in patients with metastases of colorectal adenocarcinoma. Magn Reson Imaging 1994;12:497-511.
19. 19F-MRS study in vivo. Br J Cancer 1992;65:369-375.
20. 19F magnetic resonance spectroscopy. Magn Reson Imaging 1992;10:385-392.
21. 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study. Ann Oncol 1993;4:597-602.
22. 19F nuclear magnetic resonance. Cancer Res 1994;54:4321-4326.
23. 19F nuclear magnetic resonance spectroscopy study in vivo. Cancer Chemother Pharmacol 1996;37:259-265.
24. 19F NMR monitoring of in vivo tumor metabolism after biochemical modulation of 5-fluorouracil by the uridine phosphorylase inhibitor 5-benzylacyclouridine. Magn Reson Med 1997;38:907-916.
25. 19F-NMR spectroscopy. In: Proceedings of the International Society for Magnetic Resonance in Medicine, vol 2 (abstract), Berkeley, 1997, p 1080.
26. Arellano, Malet-Martino M, Martino R, Spector T. 5-Ethynyluracil (GW776): effects on the formation of the toxic catabolites of 5-fluorouracil, fluoroacetate and fluorohydroxypropionic acid in the isolated perfused rat liver model. Br J Cancer 1997;76:1170-1180.
27. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987;47:2203-2206.
28. De Clercq E. Potential of bromovinyldeoxyuridine in anticancer chemotherapy. Anticancer Res 1986;6:549-556.
29. Desgranges C, Razaka G, De Clercq E, Herdewijn P, Balzarini J, Drouillet F. Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Res 1986;46:1094-1101.
30. Iigo M, Nishikata KI, Nakajima Y, Hoshi A, Okudaira N, Odagiri H, De Clercq E. Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5′-deoxy-5-fluorouridine against adenocarcinoma 755 in mice. Biochem Pharmacol 1989;38:1885-1889.
31. Iigo M, Nishikata KI, Nakajima Y, Hoshi A, De Clercq E. Effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine on life-span and 5-fluorouracil metabolism in mice with hepatic metastases. Eur J Cancer 1990;26:1089-1092.
32. Keizer HJ, De Bruijn EA, Tjaden UR, De Clercq E. Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2′-deoxyuridine. J Cancer Res Clin Oncol 1994;120:545-549.
33. Ogura K, Nishiyama T, Takubo H, Kato A, Okuda H, Arakawa K, Fukushima M, Nagayama S, Kawaguchi Y, Watabe T. Suicidal inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracil derived from the antiviral sorivudine. Cancer Lett 1998;122: 107-113.
34. 19F MR imaging of 5-fluorouracil and α-fluoro-β-alanine. Magn Reson Imaging 1993;11:1193-1201.
35. 19F MR imaging. Magn Reson Med 1995;34:302-307.
36. Morris HP. Studies on the development, biochemistry and biology of experimental hepatomas. Adv Cancer Res 1965;9:227-302.
37. 19F MRI: a comparative animal study. Nucl Med Biol 1996;23:897-906.
38. Brix G, Bellemann ME, Gerlach L, Haberkorn U. Intra-and extracellular fluorouracil uptake: assessment with contrast-enhanced metabolic F-19 MR imaging. Radiology 1998;209:259-267.
39. 19F MR imaging. Magn Reson Imaging 1998;17:151-155.
40. Porter DJT, Chestnut WG, Merrill BM, Spector T. Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J Biol Chem 1992;267:5236-5242.
41. Baccanari DP, Davis ST, Knick VC, Spector T. 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc Natl Acad Sci USA 1993;90:11064-11068.
42. Cao S, Rustum YM, Spector T. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 1994;54:1507-1510.
43. Khor SP, Amyx S, Davis ST, Nelson D, Baccanari DP, Spector T. Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of human data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans. Cancer Chemother Pharmacol 1997;39:223-238.
44. Mezrich R. A perspective on k-space. Radiology 1995;195:297-315.
45. 18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. Cancer Res 1997;54:3415-3423.